Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIOQUIN vs TAMBOCOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
Conversion and prevention of atrial fibrillation/flutter,Suppression of ventricular arrhythmias,Maintenance of sinus rhythm after cardioversion
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter (off-label)
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (Cr Cl < 35 m L/min).
Primarily hepatic via CYP3A4; also metabolized by CYP2D6 to active metabolite (3-hydroxyquinidine).
Hepatic metabolism via CYP2D6; active metabolite; renal excretion of unchanged drug and metabolites.
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
80-90% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
90–95% bound to albumin and alpha-1-acid glycoprotein.
Vd: 2-3 L/kg. Large Vd indicates extensive tissue distribution, with high affinity for myocardial tissue.
8–10 L/kg; extensive tissue distribution (lung, heart, liver).
Oral: 70-85% (may be reduced in heart failure). Intravenous: 100%.
Oral: 85–90% (first-pass metabolism minimal).
Cr Cl 30-50 m L/min: administer 75% of normal dose every 8-12 hours. Cr Cl 10-29 m L/min: administer 50% of normal dose every 8-12 hours. Cr Cl <10 m L/min: administer 30% of normal dose every 8-12 hours. Hemodialysis: administer after dialysis on dialysis days.
Cr Cl >50 m L/min: no adjustment; Cr Cl 35-50 m L/min: 50 mg every 12 hours; Cr Cl <35 m L/min: 100 mg every 24 hours or 50 mg every 12 hours with caution.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25% and monitor QT interval. Child-Pugh Class C: reduce dose by 50% and monitor QT interval closely.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 25-50%; Child-Pugh class C: contraindicated or use with extreme caution.
For supraventricular tachyarrhythmias: Quinidine sulfate 15-60 mg/kg/day orally divided every 6 hours; Quinidine gluconate 15-60 mg/kg/day orally divided every 8-12 hours. Maximum single dose: 400 mg. Maximum daily dose: 3 g.
Dosing not established; limited data: 1-3 mg/kg/day orally divided every 8-12 hours; maximum 6 mg/kg/day.
Initiate at lower doses (e.g., quinidine sulfate 200 mg orally every 8-12 hours) and titrate slowly due to decreased renal function and increased risk of QT prolongation and cinchonism. Monitor serum creatinine, QT interval, and quinidine levels. Adjust dose based on renal function.
Start at 50 mg every 12 hours; increase slowly with close monitoring of plasma levels and ECG; consider lower doses due to reduced renal function.
May cause fatal arrhythmias (e.g., torsade de pointes, ventricular fibrillation) especially in patients with structural heart disease, hypokalemia, or bradycardia.
May increase mortality in patients with structural heart disease (e.g., post-MI, cardiomyopathy). Reserved for life-threatening arrhythmias.
Risk of proarrhythmia; monitor ECG, electrolytes, hepatic/renal function; avoid in QT prolongation; may cause cinchonism (tinnitus, hearing loss, visual disturbances); caution in myasthenia gravis, heart failure, and hepatic impairment.
Proarrhythmic effects including new or worsened ventricular arrhythmias,Use caution in patients with conduction abnormalities (e.g., SA node dysfunction, bundle branch block),Heart failure exacerbation due to negative inotropic effects,Electrolyte disturbances (hypokalemia, hypomagnesemia) should be corrected,Plasma monitoring recommended due to narrow therapeutic index
Complete AV block without pacemaker,Long QT syndrome,Myasthenia gravis,Hypersensitivity to quinine/quinidine,Cardiogenic shock,Digitalis toxicity
Second- or third-degree AV block (unless pacemaker in place),Bifascicular block or distal conduction blocks,Cardiogenic shock or severe hypotension,Pre-existing prolonged QT interval,History of ventricular arrhythmias associated with structural heart disease
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 metabolism, increasing quinidine levels. Take with food to reduce gastrointestinal upset, but avoid high-potassium foods (e.g., bananas, oranges, spinach) if potassium levels are low.
Grapefruit juice increases flecainide AUC by 15-40% and should be avoided. High-fat meals may delay absorption but do not significantly alter overall exposure. No other specific dietary restrictions.
Quinidine, the active ingredient in CARDIOQUIN, is classified as FDA Pregnancy Category C. First trimester: Limited data, but animal studies have shown teratogenic effects at high doses. Second and third trimesters: No adequate well-controlled studies; potential risk of fetal tachycardia, thrombocytopenia, and neonatal coagulopathy. Use only if potential benefit outweighs risk.
FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trimesters: Risk of fetal arrhythmia, including tachycardia or heart block; may require fetal echocardiography. Avoid in pregnancy unless benefit outweighs risk.
Quinidine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.7-0.9. Limited data suggest low risk to nursing infant, but monitor for arrhythmias, cinchonism, and thrombocytopenia. Use with caution.
Flecainide is excreted into breast milk. Milk-to-plasma ratio approximately 2.5 (range 1.4–3.8). Infant exposure estimated at 3–5% of maternal weight-adjusted dose. Monitor infant for bradycardia, arrhythmia, and feeding difficulties. Use with caution; alternative agents preferred.
Increased volume of distribution and renal clearance in pregnancy may require dose adjustments. Monitor serum quinidine levels and titrate to therapeutic effect. Lower starting doses may be needed due to altered protein binding.
Increased plasma volume and renal clearance in pregnancy may reduce flecainide levels. Monitor therapeutic drug levels and ECG; dose adjustments may be needed (typically increased dose required). Titrate based on arrhythmia control and toxicity. Postpartum: dose may need reduction as clearance normalizes.
Cardioquin (quinidine) is a class Ia antiarrhythmic. Monitor QRS and QT intervals; risk of torsades de pointes, especially with hypokalemia or hypomagnesemia. Coadministration with digoxin requires digoxin dose reduction due to decreased clearance. Avoid in patients with myasthenia gravis, as it can exacerbate weakness. Use with caution in hepatic impairment.
Tambocor (flecainide) is a class Ic antiarrhythmic used for life-threatening ventricular arrhythmias and paroxysmal atrial fibrillation/flutter. It has a narrow therapeutic index and requires ECG monitoring for QRS prolongation (>140 ms) or new arrhythmias. Contraindicated in ischemic heart disease due to increased mortality (CAST trial). Adjust dose in renal impairment (Cr Cl < 50 m L/min: start at 50 mg q12h). Proarrhythmic risk is highest in patients with structural heart disease or reduced EF. Monitor trough levels (therapeutic range: 0.2-1.0 mcg/m L).
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any fainting, rapid heartbeat, or chest pain immediately.,Avoid grapefruit and grapefruit juice; they increase quinidine levels and risk of side effects.,Limit alcohol intake; it may increase side effects like dizziness and drowsiness.,Notify all healthcare providers you are taking quinidine.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Report any new or worsening chest pain, palpitations, fainting, or difficulty breathing immediately.,Avoid grapefruit juice as it can increase flecainide levels and risk of side effects.,Take with or without food; maintain consistent timing to keep levels stable.,Do not crush or chew extended-release capsules; swallow whole.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIOQUIN vs TAMBOCOR, answered by our medical review team.
CARDIOQUIN is a Antiarrhythmic Agent that works by Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.. TAMBOCOR is a Antiarrhythmic Agent that works by Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIOQUIN and TAMBOCOR depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIOQUIN is: Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.. The standard adult dose of TAMBOCOR is: For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIOQUIN and TAMBOCOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIOQUIN is classified as Category C. Quinidine, the active ingredient in CARDIOQUIN, is classified as FDA Pregnancy Category C. First trimester: Limited data, but animal studies have shown teratogenic effects at high . TAMBOCOR is classified as Category C. FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.